Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers

NCT04180215 is registered in ClinicalTrials.gov with Hookipa Biotech GmbH as lead sponsor.

NCT NCT04180215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04180215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers
Lead sponsor
Hookipa Biotech GmbH
Phase
Phase 1/2
Overall status
Completed
Start date
December 11, 2019
Completion date
January 9, 2025
Enrollment
198 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-related squamous cell carcinoma